PALO ALTO, Calif., July 12 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation. Telintra®, Telik's investigational drug candidate inhibitor of GSTP1-1, has recently been reported to show positive results in a Phase 2 trial in patients with MDS, a disease characterized by disordered cell proliferation and differentiation. Reprints of the publication are available from Telik.
Background on MDS
The myelodysplastic syndromes (MDS) are a heterogeneous group of
clonal hematopoietic stem cell disorders characterized by
ineffective hematopoiesis (blood cell production) involving one or
more cell lineages (red blood cells, white blood cells or
platelets) and a variable risk of transformation to acute myeloid
leukemia (AML). MDS becomes more common with age. It is
estimated that MDS affects approximately 300,000 people worldwide.
According to the American Cancer Society, 10,000–20,000
new cases of MDS are diagnosed each year in